Profil
Yanni Lin has founded Suzhou Kerui Gene Biotechnology Co., Ltd.
in 2016 and currently holds the title of Chief Scientist.
Postes actifs de Yanni Lin
| Sociétés | Poste | Début |
|---|---|---|
Suzhou Kerui Gene Biotechnology Co., Ltd.
 Suzhou Kerui Gene Biotechnology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Suzhou Kerui Gene Biotechnology Co., Ltd., also known as Cure Genetics, is a biotech company founded in 2016 by Yuan Yuan Xu, Meng Yuan Liu, and Yanni Lin. The company is based in Suzhou, China. Cure Genetics is committed to expanding the frontier of gene therapy through its innovative technology of gene editing and gene delivery. With its world-leading AAV manufacturing capability, Cure Genetics' proprietary Velptm platform enables a fast yet systematic design, selection, and optimization of AAV vectors with special features and significantly better performance of in vivo gene delivery. The Chinese company aims to provide effective treatment options for patients worldwide with unmet medical needs and to establish itself as a benchmark in the field of cell and gene therapy. | Fondateur | 01/07/2016 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Suzhou Kerui Gene Biotechnology Co., Ltd.
Suzhou Kerui Gene Biotechnology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Suzhou Kerui Gene Biotechnology Co., Ltd., also known as Cure Genetics, is a biotech company founded in 2016 by Yuan Yuan Xu, Meng Yuan Liu, and Yanni Lin. The company is based in Suzhou, China. Cure Genetics is committed to expanding the frontier of gene therapy through its innovative technology of gene editing and gene delivery. With its world-leading AAV manufacturing capability, Cure Genetics' proprietary Velptm platform enables a fast yet systematic design, selection, and optimization of AAV vectors with special features and significantly better performance of in vivo gene delivery. The Chinese company aims to provide effective treatment options for patients worldwide with unmet medical needs and to establish itself as a benchmark in the field of cell and gene therapy. | Commercial Services |
